Bone and Mineral Metabolism Disorders News

Among adults with osteoporosis on dialysis, use of denosumab significantly lowered fracture risk compared with bisphosphonate use, but cardiovascular risk was increased, according to study data.

Older women with chronic kidney disease who take denosumab may have a higher risk for emergently treated hypocalcemia compared with those treated with bisphosphonates, according to published data.

Effective Jan. 1, 2025, CMS will begin including phosphate-binders in the end-stage renal disease prospective payment system bundle.

Urea reduction ratio — a metric of hemodialysis efficacy in removing urea — may predict skeletal muscle mass for adults on maintenance hemodialysis, according to research published in the Journal of Renal Nutrition.

Changes in body composition may correlate with bone mineral density fluctuations in non-dialysis-dependent chronic kidney disease, according to a cohort study.

Approximately 23% of patients with chronic kidney disease meet the criteria for gout, of whom 13% have uncontrolled gout and 36% have no formal gout diagnosis, according to data published in Gout, Urate, and Crystal Deposition Disease.

Diabetes mellitus may modify the link between chronic kidney disease-mineral and bone disorder biomarkers and aortic stiffness in adults on peritoneal dialysis, according to recently published data.

The FDA has added a boxed warning for denosumab to advise patients with advanced chronic kidney disease of an increased risk for severe hypocalcemia, according to an FDA drug safety communication.

Long-term use of the potassium binder patiromer may improve clinical outcomes among patients with chronic kidney disease and hyperkalemia, according to a study.